Heterocyclic Compounds

Matches 201 - 250 out of 33,959	< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >

Document	Document Title
WO/2024/030968A1	COMPOUNDS FOR MODULATING RET PROTEIN The present disclosure relates to protein degradation-inducing compounds for protooncogene tyrosine-protein kinase receptor (RET), which may be either wild type RET or a mutant form of RET useful in the treatment of diseases and disorder...
WO/2024/031089A1	SARS-COV2 MAIN PROTEASE INHIBITORS The present disclosure relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.
WO/2024/030647A1	COMPOSITIONS AND METHODS FOR INHIBITION OF RAS Provided herein are compounds, or salts, esters, tautomers, prodrugs, zwitterionic forms, or stereoisomers thereof, as well as pharmaceutical compositions comprising the same. Also provided herein are methods of using the same in modulat...
WO/2024/030504A1	PREDICTIVE BIOMARKERS AND USE THEREOF TO TREAT PARKINSON'S DISEASE The invention provides methods of treating patients with Parkinson's disease (PD) associated with wild-type LRRK2. The invention recognizes that analysis of biomarkers in such patients allows identification of those patients who will res...
WO/2024/029292A1	COMPOSITION, COMPOUND, AND METHOD FOR MANUFACTURING SEMICONDUCTOR SUBSTRATE The purpose of the present invention is to provide a method for manufacturing a semiconductor substrate using a composition capable of forming a film having excellent etching resistance; and to provide said composition. The composition a...
WO/2024/030835A2	NOVEL SALTS AND CRYSTALS The disclosure provides new, stable, crystalline salt forms of lumateperone, together with methods of making and using them, and pharmaceutical compositions comprising them.
WO/2024/027751A1	CRYSTAL FORM OF HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF Disclosed are a crystal form of a heterocyclic compound, a preparation method therefor, and the use thereof. The heterocyclic compound is the compound represented by formula I. For the crystal form thereof, the X-ray powder diffraction p...
WO/2024/030633A1	COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS Provided herein are compounds, or salts, esters, tautomers, prodrugs, zwitterionic forms, or stereoisomers thereof, as well as pharmaceutical compositions comprising the same. Also provided herein are methods of using the same in modulat...
WO/2024/027792A1	PROTEIN KINASE DEGRADING AGENT, MEDICAMENT AND USE The present invention belongs to the field of biomedical technology, and is specifically directed to a compound useful as protein kinase degrading agent, pharmaceutical composition comprising the same and the use thereof. The compound us...
WO/2024/027116A1	DIHYDROIMIDAZO-PYRIMIDINONE COMPOUNDS AS LP-PLA2 INHIBITORS AND USE THEREOF Provided are compounds of Formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R2, R3, R4, Q, n, and A are described herein, which are useful as Lp-PLA2 inhibitors, pharmaceutical compositions comprising the ...
WO/2024/027790A1	USE OF PYRROLOPYRIMIDINE COMPOUND IN TREATMENT OF ACUTE GRAFT VERSUS HOST DISEASE Provided is the use of a pyrrolopyrimidine compound in the treatment of acute graft versus host disease, in particular the use of a compound of formula I, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof in the treat...
WO/2024/027370A1	NITROGEN-CONTAINING FUSED THREE RING PRMT5 INHIBITOR, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF A PRMT5 inhibitor having a structure of formula (I), a preparation method therefor, a pharmaceutical composition containing same, the use thereof as a PRMT5 inhibitor, and the use thereof in the treatment and/or prevention of PRMT5-media...
WO/2024/027814A1	COMPOUND HAVING KRAS G12D INHIBITORY EFFECT Disclosed are a compound as represented by formula (I) having a KRas G12D inhibitory effect, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, and the use thereof in the preparation of a drug for KRas G12D-related...
WO/2024/028245A1	PIPERIDINYLPYRIDINYLCARBONITRILE DERIVATIVES AS INHIBITORS OF GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE AND GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE PROTEIN The present disclosure provides certain piperidinylpyridinylcarbonitrile derivatives, and pharmaceutically acceptable salts thereof, that are inhibitors of Glutaminyl -peptide cyclotransferase (QPCT) and glutaminyl-peptide cyclotransfera...
WO/2024/022186A1	METHYLPYRAZOLE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR AND USE THEREOF The present invention relates to a methylpyrazole compound, a pharmaceutical composition comprising same, a preparation method therefor, and use thereof. In particular, the present invention relates to a compound represented by formula (...
WO/2024/022508A1	KIF18A INHIBITOR AND USE Provided are a heterocyclic compound as represented by formula I, and a tautomer, a stereoisomer, a hydrate, a solvate, a pharmaceutically acceptable salt or a prodrug thereof. The compound has a relatively good KIF18A inhibition effect.
WO/2024/023287A1	[4-[5-(METHYLSULFONYL)-PHENYL]PIPERAZIN-1-YL]-(PHENYL)METHANONE DERIVATIVES AND SIMILAR COMPOUNDS WITH GFR ALPHA 1-RET ACTIVITY AS NEUROPROTECTIVE AGENTS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS The present invention relates to a compound of general formula (I). The invention further relates to the compounds of the invention as neuroprotective and/or neurorestorative agents, in particular for use in the treatment of neurological...
WO/2024/023259A1	CHLOROPHYLLIDE DERIVATIVES FOR USE IN THE PREVENTION OR TREATMENT OF BACTERIAL INFECTION The present invention relates to a compound of formula I, a stereoisomer, a tautomer and/or a dimer thereof or a salt thereof, (I) wherein M is a metal among the group of Mg, Cu and Zn; R1 is a methyl group or a formyl group; R2 is a car...
WO/2024/026056A2	HETEROARYL COMPOUNDS AS EGFR INHIBITORS AND THEIR USES Disclosed are heteroaryl compounds and pharmaceutical compositions thereof, which are useful for inhibiting EGFR, as well as methods for using such compounds to treat cancer associated with an EGFR or HER2 exon 20 insertion mutation.
WO/2024/023836A1	POLYMORPHIC FORM OF LAROTRECTINIB SULFATE The present invention provides a crystalline Form M1 of Larotrectinib sulfate and process for the preparation of the same optionally in presence of a coformer.
WO/2024/022275A1	CRYSTAL FORM OF XEVINAPANT, METHOD FOR PREPARING SAME AND USE THEREOF The present invention relates to a crystal form of compound Xevinapant and a method for preparing same, a pharmaceutical composition containing same, and use thereof in the preparation of an inhibitor drug for inhibitors of apoptosis pro...
WO/2024/023284A1	NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS The present invention relates to a compound of general formula (I) or a pharmaceutically acceptable salt and/or solvate thereof. The invention further relates to the use of the compounds of the invention as neuroprotective and/or neurore...
WO/2024/022519A1	HETEROCYCLE FUSED PYRIMIDINE COMPOUND AND USE THEREOF Provided are a compound of formula (I) or a pharmaceutically acceptable salt thereof as a USP1 inhibitor and a pharmaceutical composition comprising the compound or the pharmaceutically acceptable salt thereof. The compound and the pharm...
WO/2024/024438A1	CLATHRATE COMPOUND AND METHOD FOR PRODUCING SAME, POLYMERIZABLE COMPOSITION, RESIN COMPOSITION, POLYMER, CURED PRODUCT, AND LAMINATE A clathrate compound containing a host molecule and a guest molecule in which the host molecule is a compound represented by formula (1) or a cyclic oligosaccharide and the guest molecule is a squarylium compound represented by formula (...
WO/2024/026128A2	TRICYCLIC ARYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF The invention provides novel tricyclic aryl compounds and derivatives thereof, and pharmaceutical compositions thereof and methods for treating diseases and disorders, such as various types of cancer.
WO/2024/022266A1	HETEROARYL COMPOUNDS AS INHIBITORS OF USP1 The disclosure is related to a series of novel heteroaryl derivatives as USP1 inhibitors useful for the treatment of diseases or conditions, such as cancers, especially cancers with BRCA mutations or HR deficiencies. Specifically, provid...
WO/2024/026064A1	ENHANCING ANTIMETASTASIS ACTIVITY USING TARGETED PROTEIN DEGRADATION The current invention relates to transcription elongation factor eEFlA2-targeted protein degradation ligands and pharmaceutical compositions thereof and their utility as anti-cancer agents.
WO/2024/026256A1	SUBSTITUTED IMIDAZOPYRAZINE COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK3 Provided herein are compounds and compositions thereof for modulating IRAK3. In some embodiments, the compounds and compositions are provided for treatment of cancer.
WO/2024/026076A2	SUBSTITUTED 3,4-DIHYDROQUINOLINONE INHIBITORS OF TSHR Disclosed are compounds that are thyroid stimulating hormone receptor antagonists, and methods useful for preventing or treating a thyroid disease.
WO/2024/026260A1	SUBSTITUTED IMIDAZOPYRAZINE COMPOUNDS AS IRAK3 BINDERS Provided herein are compounds and compositions thereof that bind to IRAK3.
WO/2024/026081A1	TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPY The present invention relates to quinazolinones and related compounds which degrade PARP14 and are useful, for example, in the treatment of cancer and inflammatory diseases.
WO/2024/023266A1	NOVEL COMPOUNDS The present invention relates to novel compounds for the treatment, alleviation or prevention of a group of diseases, disorders and abnormalities which are responsive to the modulation or inhibition of the activation of a component of th...
WO/2024/020517A1	3-(6-PYRIDIN-3-YL)-2-[4-(4-METHYL-4H-1,2,4-TRIAZOL-3-YL)PIPERIDIN-1-YL]BENZONITR ILE DERIVATIVES AND SIMILAR COMPOUNDS AS QPCTL AND QPCT INHIBITORS FOR THE TREATMENT OF CANCER Provided herein are compounds of formula (II) and formula (I) that are inhibitors of QPCTL and QPCT: (II) & (I) Also provided are pharmaceutical compositions comprising the compounds, as well as the compounds for use in methods for the t...
WO/2024/017384A1	COMPOUND FOR RECOVERING P53 MUTATION FUNCTION AND USE THEREOF Provided are a compound for recovering a p53 mutation function and use thereof, particularly relating to a compound represented by formula M, or an enantiomer, a diastereoisomer, a racemate, a tautomer, a stereoisomer, a geometric isomer...
WO/2024/017876A1	HETEROARYL DERIVATIVES AS DDRs INHIBITORS The present invention relates to compounds of formula (I) inhibiting Discoidin Domain Receptors (DDR inhibitors), methods of preparing such compounds, intermediate compounds useful in such preparations, pharmaceutical compositions contai...
WO/2024/019103A1	HETEROCYCLIC COMPOUND THAT ACTS ON G12D MUTANT KRAS PROTEIN Provided is a compound that is effective as an active ingredient in a therapeutic pharmaceutical composition for pancreatic cancer.　Having studied compounds that are effective as active ingredients in a therapeutic pharmaceutical compo...
WO/2024/020380A1	QUINAZOLINE COMPOUNDS AND METHODS OF USE Substituted quinazoline compounds, conjugates, and pharmaceutical compositions for use in the treatment of cancer are disclosed herein. The disclosed compounds are useful, among other things, in the inhibition of CDK. In certain aspects,...
WO/2024/017880A1	IMIDAZOTRIAZINE DERIVATIVES AS IL-17 MODULATORS A series of substituted imidazo[l,2-b][l,2,4]triazine derivatives of Formula (I) as defined herein, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments,...
WO/2024/020522A1	COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF IRAK-4 The present disclosure relates to compounds that act as degraders of IRAK-4 protein kinase; pharmaceutical compositions comprising compounds of Formula (I); and methods of treating diseases and disorders associated with cancer and inflam...
WO/2024/017877A1	HETEROARYL DERIVATIVES AS DDRs INHIBITORS The present invention relates to compounds of formula (I) inhibiting Discoidin Domain Receptors (DDR inhibitors), methods of preparing such compounds, intermediate compounds useful in such preparations, pharmaceutical compositions contai...
WO/2024/017365A1	PHARMACEUTICALLY ACCEPTABLE SALT AND POLYMORPH OF SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDIN-7-AMINE DERIVATIVE AND USE THEREOF The present application relates to a pharmaceutically acceptable salt and polymorph of a substituted pyrazolo[1,5-a]pyrimidin-7-amine derivative as represented by formula (I), a pharmaceutical composition comprising same, a preparation m...
WO/2024/017144A1	SUBSTITUTED IMIDAZO [1, 2-A] PYRIDINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT AND PREVENTION OF FIBROSIS Provied are a class of substituted imidazo[1,2-a]pyridine compounds, pharmaceutical compositions containing the same, and use of the compounds in the treatment and prevention of fibrosis.
WO/2024/020419A1	AZA-QUINAZOLINE COMPOUNDS AND METHODS OF USE Substituted aza-quinazoline compounds, conjugates, and pharmaceutical compositions for use in the treatment of cancer are disclosed herein. The disclosed compounds are useful, among other things, in the inhibition of CDK. In certain aspe...
WO/2024/017178A1	SUBSTITUTED HYDANTOIN COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS Provided herein are substituted hydantoin compounds, e.g., a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms o...
WO/2024/020333A2	KINASE INHIBITORS Disclosed is a class of kinase inhibitors. Related pharmaceutical compositions and methods of making and using the kinase inhibitors are also disclosed.
WO/2024/020034A1	CBL-B INHIBITORS AND METHODS OF USE THEREOF Disclosed herein are compounds that are Cbl-b inhibitors having a structure according to Formula (II), and compositions containing those compounds. Methods of preparing the compounds, and methods of using the compounds for the treatment ...
WO/2024/020534A2	CYCLIC COMPOUNDS AND METHODS OF USING SAME The present application relates to compounds of Formula (I), as defined herein, and pharmaceutically acceptable salts thereof. The present application also describes pharmaceutical composition comprising a compound of Formula (I), and ph...
WO/2024/017294A1	PREPARATION AND USE OF QUINAZOLINONE DERIVATIVE AS KINASE INHIBITOR Disclosed are a compound represented by formula I, a stereoisomer, deuterated product or pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing same, as well as a use thereof as a BRAF modulator in the prepa...
WO/2024/017270A1	SPIRO COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF The present application relates to the technical field of chemical drugs, and to a spiro compound as represented by general formula (I), or an isomer, racemate, or pharmaceutically acceptable salt thereof, as a 3C-like protease inhibitor...
WO/2024/017857A1	NOVEL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE SULFONAMIDE DERIVATIVES The invention relates to novel compounds having the general formula I wherein R1, R2, X1, X2,X3 and W are as described herein, composition including the compounds and methods of using the compounds.

Matches 201 - 250 out of 33,959	< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >